Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Varsha Gandhi, PhD, on Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Jan

Today In Oncology

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Varsha Gandhi, PhD, on Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Triplet Therapy Demonstrates Superior Progression-Free Survival in First-Line dMMR-MSI-H Metastatic Colorectal Cancer

Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer

HER2-Positive Gastroesophageal Cancer Zanidatamab Plus Chemotherapy Prolongs Progression-Free Survival

Improved Contralateral Breast Cancer Risk Knowledge With Personalized Counseling Tool

Machine Learning–Guided Optical Biopsy Accurately Identifies Malignant Lung Nodules Intraoperatively